Hydrazine Containing Patents (Class 564/148)
-
Patent number: 6762204Abstract: One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.Type: GrantFiled: July 10, 2002Date of Patent: July 13, 2004Assignee: Synta Pharmaceuticals, Inc.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono, Zhi-Qiang Xia
-
Patent number: 6706765Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.Type: GrantFiled: February 6, 2003Date of Patent: March 16, 2004Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L. Fedde, Carl R. Illig, Thomas P. Markotan, Thomas P. Stagnaro
-
Publication number: 20040039025Abstract: A method for the inhibition of high affinity glycine transporters, compounds that inhibit these transporters; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of disease states in which glycine is involved are disclosed.Type: ApplicationFiled: August 28, 2003Publication date: February 26, 2004Inventors: Syed M. Ali, Kurt R. Brunden, Dario Doller, Brian Herbert, Jack B. Jiang, Amy Jordan
-
Publication number: 20030195258Abstract: Disclosed is a compound represented by the Structural Formula (I): 1Type: ApplicationFiled: January 15, 2003Publication date: October 16, 2003Applicant: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono
-
Publication number: 20030162814Abstract: The novel compounds of formula (I), wherein R1, R2, R2′, R2″, R3, R4, R5, R5′, R5″, R5′″, R″″, X, Y, U, V and W have the meanings given in patent claim no. 1, are inhibitors of the coagulation factors Xa and VIIa and can be used for treating thromboses, myocardial infarction, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis following angioplasty, intermittent claudication, tumours, tumour diseases and/or tumour metastases.Type: ApplicationFiled: January 23, 2003Publication date: August 28, 2003Inventors: Horst Juraszyk, Dieter Dorsch, Werner Mederski, Christos Tsaklakidis, Christopher Barnes, Johannes Gleitz
-
Patent number: 6596863Abstract: Process for producing a nitroetheneamine derivative or its stereoisomer, its tautomer or a salt thereof comprising reacting a compound of the formula with a compound of the formula R6—CH2NO2 to obtain a compound of the formula and reacting the resulting compound with a compound of the formulaType: GrantFiled: April 29, 2002Date of Patent: July 22, 2003Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Fuminori Kato, Keizo Miyata, Hirohiko Kimura, Kazuhiro Yamamoto, Hiroyuki Ikegami, Hiromi Takeo
-
Publication number: 20030125360Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.Type: ApplicationFiled: July 12, 2001Publication date: July 3, 2003Applicant: Biotie Therapies Corp.Inventors: David John Smith, Ferenc Fulop, Marjo Pihlavisto, Laszlo Lazar, Sakari Alaranta, Petri Vainio, Zsolt Szakonyi
-
Publication number: 20030119914Abstract: Disclosed is a compound represented by the Structural Formula (I): 1Type: ApplicationFiled: July 10, 2002Publication date: June 26, 2003Applicant: Shionogi BioResearch Corp.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono
-
Patent number: 6528685Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.Type: GrantFiled: October 19, 1999Date of Patent: March 4, 2003Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.Inventors: Sasson Cohen, Yaacov Herzig, Ruth Levy, Mitchell Shirvan, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg
-
Patent number: 6518310Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.Type: GrantFiled: March 16, 2001Date of Patent: February 11, 2003Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L Fedde, Carl R Illig, Thomas P. Markotan, Thomas P Stagnaro
-
Publication number: 20020193614Abstract: Novel anthranilic acid derivatives having an inhibiting activity of cGMP-PDE are represented by the formula I where A is a lower alkylene group: 1Type: ApplicationFiled: January 18, 2002Publication date: December 19, 2002Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Teruo Oku, Noriko Oku, Chikako Oku, Tomohito Oku, Kozo Sawada, Akio Kuroda, Takayuki Inoue, Natsuko Kayakiri, Yuki Sawada, Tsuyoshi Mizutani
-
Publication number: 20020173469Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.Type: ApplicationFiled: May 30, 2002Publication date: November 21, 2002Applicant: SmithKline Beecham CorporationInventor: Dennis Shinji Yamashita
-
Patent number: 6455515Abstract: Salicylohydrazide derivatives of the formula I in which the index and the substituents have the following meanings: X is halogen, NO2, cyano, alkyl or alkoxy; m is 0, 1, 2 or 3, it being possible for the substituents X to differ from each other if n is greater than 1; R1 is NO2, NH2 or NH—CO—A; A is hydrogen, alkyl, alkoxy, NH2, NHCH3 or N(CH3)2; R2 is hydrogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or alkylthio; it being possible for the hydrocarbon radicals to be unsubstituted or substituted, R3 is phenyl, naphthyl, cycloalkyl, 5-membered or 6-membered hetaryl or 5-membered or 6-membered heterocyclyl containing one to three N atoms and/or one O or S atom or one or two O and/or S atoms, the ring systems being unsubstituted or substituted; the preparation of these compounds, compositions comprising them, and their use for controlling harmful fungi.Type: GrantFiled: June 14, 2001Date of Patent: September 24, 2002Assignee: BASF AktiengesellschaftInventors: Andreas Gypser, Thomas Grote, Joachim Rheinheimer, Ingo Rose, Peter Schäfer, Oliver Cullmann, Markus Gewehr, Wassilios Grammenos, Jordi Tormo i Blasco, Bernd Müller, Hubert Sauter, Eberhard Ammermann, Siegfried Strathmann, Gisela Lorenz, Reinhard Stierl
-
Patent number: 6451792Abstract: A medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): wherein the substituents are as defined in the disclosure, its stereoisomers, its tautomers or a salt thereof.Type: GrantFiled: March 20, 2001Date of Patent: September 17, 2002Assignee: Ishihara Sangyo Kaisha Ltd.Inventors: Fuminori Kato, Keizo Miyata, Hirohiko Kimura, Kazuhiro Yamamoto, Hiroyuki Ikegami, Hiromi Takeo
-
Publication number: 20020127605Abstract: The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo- or heterocyclic groups are attached to a central saturated, partially saturated, or aromatic 5-6 membered carbocyclic ring by a combination of straight or branched linker chains. The invention further relates to pharmaceutical compositions comprising one or more of the said compounds, and to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders, such as neurological disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.Type: ApplicationFiled: November 28, 2001Publication date: September 12, 2002Inventors: Gregory S. Hamilton, Sergei Belyakov, Mark Vaal, Ling Wei, Yong-Qian Wu, Joseph P. Steiner
-
Patent number: 6444848Abstract: Process for the preparation of symmetrical diacylhydrazines having general formula (I): R1—CO—NH—NH—CO—R1 wherein R1 represents a linear or branched C1-C18 alkyl group; a linear or branched C2-C8 alkoxyalkyl group; a C2-C8 cyanoalkyl group; a C5-C8 cycloalkyl group, said cycloalkyl group optionally containing a heteroatom selected from oxygen, nitrogen and sulfur; a C6-C18 aryl group; a C7C20 arylalkyl group or alkylaryl group, said arylalkyl or alkylaryl groups optionally substituted with one or more hydroxyl groups, or with one or more linear or branched C1-C8 alkoxyl groups; comprising: (a) reacting an ester of a carboxylic acid having general formula (II): R1—CO—OR2 wherein R1 has the same meanings defined above and R2 represents a linear or branched C1-C18 alkyl group, with hydrazine, in its pure or hydrated state, obtaining a monoacylhydrazine having general formula (III): R1—CO—NH—NH2; (b) reacting the monoacylhydrazine having general formulaType: GrantFiled: March 9, 2001Date of Patent: September 3, 2002Assignee: Great Lakes Chemical (Europe) GmbHInventors: Fabio Broussard, Carlo Neri, Flavio Somenzi
-
Publication number: 20020120149Abstract: A method for the inhibition of high affinity glycine transporters, compounds that inhibit these transporters; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of disease states in which glycine is involved are disclosed.Type: ApplicationFiled: September 7, 2001Publication date: August 29, 2002Inventors: Syed M. Ali, Kurt R. Brunden, Dario Doller, Brian Herbert, Jack B. Jiang, Amy Jordan
-
Patent number: 6365745Abstract: The present invention provides a method for producing a hydrazine derivative of the formula [2]: wherein R1 is alkyl group having 1-12 carbon atoms and the like, R2 is alkyl group having 1-12 carbon atoms and the like, and Ar is phenylene group and the like, from a hydrazone derivative of the formula [1] wherein R1, R2 and Ar are as defined above, in the presence of at least one base selected from the group consisting of an organic base and an inorganic base, and a metal hydrogenating catalyst. By this method, reduction proceeds selectively and a hydrogenolysis reaction (side reaction) can be suppressed.Type: GrantFiled: July 13, 2001Date of Patent: April 2, 2002Assignee: Sumika Fine Chemicals Co., Ltd.Inventors: Kozo Matsui, Kiyoshi Sugi, Hiromi Suga, Nobushige Itaya
-
Salicylic acid derivatives, processes for their preparation, compositions comprising them, their use
Publication number: 20020032178Abstract: Salicylic acid derivatives of the formula I, 1Type: ApplicationFiled: July 2, 2001Publication date: March 14, 2002Inventors: Andreas Gypser, Thomas Grote, Joachim Rheimheimer, Ingo Rose, Oliver Cullmann, Markus Gewehr, Wassilios Grammenos, Jordi Tormo i Blasco, Bernd Muller, Hubert Sauter, Eberhard Ammermann, Siegfried Strathmann, Gisela Lorenz, Reinhard Stierl -
Publication number: 20010044464Abstract: The present invention relates to a hydrazine oxoacetamide derivative or its salt which exhibits an excellent insecticidal effect even at a low concentration.Type: ApplicationFiled: April 19, 2001Publication date: November 22, 2001Applicant: AGRO-KANESHO CO., LTD.Inventors: Syuichi Usui, Kiyoshi Takasuka, Yukinori Takekita, Junko Uchida, Norio Osaki
-
Patent number: 6319894Abstract: There is disclosed a complex and a combination of the glycosylated polypeptide fetuin and a therapeutically active small molecule compound having a net positive charge at physiological pH. The presence of fetuin as a drug complex or in combination with the therapeutically active small molecule compound enhances therapeutic activity of the small molecule compound. The present invention further provides a means for screening for therapeutically active small molecule compounds by means of binding to fetuin.Type: GrantFiled: January 8, 1997Date of Patent: November 20, 2001Assignee: The Picower Institute for Medical ResearchInventors: Kevin Tracey, Haichao Wang
-
Publication number: 20010031894Abstract: A method is provided for the transition metal-catalyzed arylation, or vinylation, of hydrazines, hydrazones, and the like. Additionally, the invention provides a conceptually novel strategy, the cornerstone of which is the transition metal-catalyzed arylation or vinylation method, for the synthesis of indoles, carbazoles, and the like. The methods and strategies of the invention may be utilized in standard, parallel, and combinatorial synthetic protocols.Type: ApplicationFiled: January 18, 2001Publication date: October 18, 2001Inventors: Stephen L. Buchwald, Seble Wagaw, Oliver Fabian Geis
-
Patent number: 6271263Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.Type: GrantFiled: March 2, 1999Date of Patent: August 7, 2001Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Benjamin Sklarz, Ramy Lidor, Eliezer Bahar, Yaacov Herzig, Jeff Sterling, Alex Veinberg
-
Patent number: 6235787Abstract: Hydrazine derivatives of the formula wherein Y is CO or SO2; R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is lower alkyl, halo-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl or aryl when Y is SO2 and is lower alkyl, halo-lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, lower cycloalkyl, aryl, aryl-lower alkyl, aryl-lower alkoxy or NR5R6 when Y is CO; and R3 is hydrogen, lower alkyl optionally substituted by cyano, amino, hydroxy, lower alkoxy, lower alkoxycarbonyl, heterocyclyl or heterocyclylcarbonyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl or heterocyclyl; or R2 and R3 together form the residue of a 5-, 6- or 7-membered cyclic amide, cyclic imide, cyclic sulphonamide or cyclic urethane group; R4 is lower alkyl, hydroxy-lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula X-aryl, X-heteroarType: GrantFiled: June 16, 1998Date of Patent: May 22, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Michael John Broadhurst, William Henry Johnson, Daryl Simon Walter
-
Patent number: 6177594Abstract: Benzamides of the formula I: wherein R1 and R2 independently of one another are each alkyl having 1-6 C atoms, or R1 and R2 together are alkylene, and their salts, are suitable as intermediates in the synthesis of drugs.Type: GrantFiled: December 9, 1998Date of Patent: January 23, 2001Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Andreas W{umlaut over (a)}chtler, Margit Stern, Volker Reiffenrath
-
Patent number: 6172108Abstract: Compounds of formula (I): R—NH—A—CO—NH—NH—(W)n—Z (I) wherein: n is 0 or 1, W represents —CO— or S(O)r wherein r is 0, 1 or 2, Z represents a group selected from aryl, arylalkyl, heteroaryl and heteroarylalkyl, each optionally substituted, R represents a grouping selected from: Z1—T—CO—, Z1—O—T—CO—, Z1—T—O—CO—, Z1—T—S(O)q— wherein Z1, T and q are as defined in the description, A represents alkylene, alkenylene or alkynylene each having from 3 to 8 carbon atoms, alkylenecycloalkylene, cycloalkylenealkylene, alkylenecycloalkylenealkylene, alkylenearylene, arylenealkylene, alkylenearylenealkylene a grouping wherein B1 is as defined in the description, or A forms with the adjacent nitrogen atom a grouping as defined in the description, and medicinal products containing the same which are useful as Neuropeptide Y receptorType: GrantFiled: December 16, 1999Date of Patent: January 9, 2001Assignee: Adir et CompagnieInventors: Antonio Monge Vega, Ignacio Aldana Moraza, Daniel-Henri Caignard, Jacques Duhault, Jean Boutin, Odile Dellazuana
-
Patent number: 6096890Abstract: This invention provides a convenient process for the preparation of monoacylhydrazines from carboxylic acids or their salts and hydrazine or substituted hydrazine in the presence of a 1,3,5-triazine substituted with at least one chloro or fluoro. The resulting monoacylhydrazine can further be converted to a diacylhydrazine by effectively either repeating the reaction or through reaction with a carboxylic acid chloride.Type: GrantFiled: August 25, 1999Date of Patent: August 1, 2000Assignee: Rohm and Haas CompanyInventors: Catherine Dubuisson-Brengel, Heather Lynnette Rayle
-
Patent number: 6063819Abstract: Neuroprotective drugs are disclosed with at least 3 branches extending outwardly from a center atom or group, each branch having a guanidino group at its terminus. All branches preferably should be identical, and distributed around the center atom or group in a radial manner. Three branches can be bonded to a nitrogen atom, or four branches can be coupled to a carbon atom; other center groups include stable aromatic, cycloalkyl, heterocyclic, or bicyclic structures. Starting reagents are disclosed with a center atom or group, and with reactive groups (such as primary amines or hydroxyl groups) at the ends of short "spacer chains" bonded to the center atom or group. Reagents derived from arginine (an amino acid having a terminal guanidino group) can be bonded to these center components, using protective groups on the arginyl reagents to ensure desired final products with accessible guanidino groups at the ends of spacer chains.Type: GrantFiled: February 18, 1998Date of Patent: May 16, 2000Assignee: Cypros Pharmaceutical Corp.Inventors: Paul J. Marangos, Brian W. Sullivan, Torsten Wiemann, Anne M. Danks, Marina Sragovicz, Lewis R. Makings
-
Patent number: 6015904Abstract: This invention provides novel reagents for the preparation of radiopharmaceuticals useful as imaging agents for the diagnosis of cardiovascular disorders, infection, inflammation and cancer, diagnostic kits comprising said reagents and intermediate compounds useful for the preparation of said reagents. The reagents are comprised of stable hydrazone modified biologically active molecules that react with gamma emitting radioisotopes to form radiopharmaceuticals that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy.Type: GrantFiled: October 23, 1997Date of Patent: January 18, 2000Inventors: Michael Sworin, Milind Rajopadhye, Thomas David Harris, David Scott Edwards, Edward Hollister Cheesman, Shuang Liu
-
Patent number: 5989774Abstract: A silver halide photographic material is disclosed containing a new type of hydrazide compound represented by following general formula I, the different symbols of which are defined in the description. ##STR1## In a preferred embodiment Q is pyridinium, substituted with a propargyllic group or butynyl group.The photographic material is preferably a graphic arts recording material. High gradation and excellent hard dot quality are obtained.Type: GrantFiled: September 10, 1998Date of Patent: November 23, 1999Assignee: Agfa-Gevaert, N.V.Inventors: Johan Loccufier, Stefaan Lingier, Paul Callant, Sabine Emmers
-
Patent number: 5981138Abstract: A hydrazine compound represented by the following formula (I):Ar.sub.1 --NH--NH--G.sub.1 --R.sub.1 (I)wherein Ar.sub.1 represents an aromatic group; G.sub.1 represents a carbonyl group, a sulfonyl group, a sulfoxy group, a phosphoryl group, an oxalyl group or an iminomethylene group; R.sub.1 represents a hydrogen atom or a block group; and at least one of Ar.sub.1 and R.sub.1 has a group represented by the following formula (II): ##STR1## wherein * represents a bond for connecting directly or through a liking group to Ar.sub.1 or R.sub.1 ; Z represents a nonmetallic atom group capable of forming a 5- or 6-membered unsaturated heterocyclic ring having a conjugated positive charge; and X.sup.- represents --O.sup.-, --S.sup.- or --N.sup.- --R.sub.2, wherein R.sub.2 represents an alkyl group, an alkenyl group, an alkynyl group, an aryl group or a heterocyclic group. Also disclosed is a silver halide photographic light-sensitive material containing the hydrazine compound.Type: GrantFiled: September 4, 1997Date of Patent: November 9, 1999Assignee: Fuji Photo Film Co., Ltd.Inventors: Hiroyuki Suzuki, Kohzaburoh Yamada, Hiroshi Takeuchi, Toshihide Ezoe, Takashi Hoshimiya
-
Patent number: 5962722Abstract: An .alpha.-hydrazino acid derivative of general formula (I) is described, wherein R.sub.1, R.sub.2, R.sub.3 are hydrogen or a carbon radical, such that when R.sub.2 and R.sub.3 are different, C* is an asymmetric carbon of L, D or DL configuration, and R.sub.4 and R.sub.5 are a protecting group, characterized in that R.sub.4 is a benzyl ArCH.sub.2 radical of formula (a), wherein Ar is a phenyl radical or phenyl substituted by one or more X groups; X being hydrogen, halogen, a nitro or alkyl radical; and in that R.sub.5 is a Y--O--CO group, where Y is a carbon radical different from R.sub.4.Type: GrantFiled: March 3, 1998Date of Patent: October 5, 1999Assignee: Centre National de la Recherche ScientifiqueInventors: Andre Collet, Joelle Vidal, Jean-Christophe Hannachi, Laure Guy
-
Patent number: 5942644Abstract: The disclosure describes new compositions of matter useful for the preparation of optically-active vicinal aminoalcohols. The compositions are chiral .beta.-hydroxycarboxamides, .beta.-hydroxyhydraxides, and .beta.-hydroxyhydroxamic acids.Type: GrantFiled: September 15, 1997Date of Patent: August 24, 1999Assignee: BioCatalytics, Inc.Inventor: J. David Rozzell, Jr.
-
Patent number: 5929281Abstract: A heterocyclic aromatic halide or an aryl halide is reacted with an amine compound in the presence of a base to give a heterocyclic aromatic amine or an arylamine, respectively. In this reaction, a catalyst comprising a palladium compound and a tertiary phosphine is used for the preparation of a heterocyclic aromatic amine, and a catalyst comprising a palladium compound and a trialkylphosphine is used for the preparation of an arylamine.Type: GrantFiled: April 15, 1997Date of Patent: July 27, 1999Assignee: Tosoh CorporationInventors: Masakazu Nishiyama, Yasuyuki Koie
-
Patent number: 5912352Abstract: The invention relates to a novel process for the preparation of compounds of formula I ##STR1## wherein R.sub.1 is hydrogen or a suitable amino-protecting group,R.sub.2 is unsubstituted or substituted alkyl,R.sub.3 is hydrogen, aryl, heterocyclyl, unsubstituted or substituted alkyl or unsubstituted or substituted cycloalkyl,R.sub.4, independently of R.sub.1, is hydrogen or a suitable amino-protecting group andm is a number from 1 to 7; and wherein further suitable protecting groups for functional groups may be present; which compounds are antivirally active or can be used as starting materials for pharmaceutically active, especially antiviral compounds.Type: GrantFiled: May 30, 1997Date of Patent: June 15, 1999Assignee: Novartis Finance CorporationInventors: Alexander Fassler, Guido Bold, Hans-Georg Capraro, Heinz Steiner
-
Patent number: 5811456Abstract: Novel monoamine oxidase B inhibitors of formula (I), wherein R.sub.1 .dbd.H, an optionally substituted benzyloxy or phenylethoxy group; p=0-3; R.sub.3 .dbd.H, a CN, OH, CCH group, a C.sub.1 -C.sub.3 alkoxy-carbonyl group, or a C.sub.1 -C.sub.3 alkylated cyanomethyl group; R.sub.2 .dbd.H or a C.sub.1 -C.sub.3 alkyl group; n=0 or 1; if n=0, R.sub.4 is a C.sub.1 -C.sub.3 alkyl group or a C.sub.1 -C.sub.3 alkoxy group, while if n=1, y=1 and R.sub.4 is a C.sub.1 -C.sub.3 alkyl group, a C.sub.1 -C.sub.3 alkoxy group or a phenyl group. The invention also concerns processes for the preparation of said novel inhibitors and the therapeutic use thereof.Type: GrantFiled: August 6, 1996Date of Patent: September 22, 1998Assignees: Laboratoires Mayoly Spindler, Michel SemanInventors: Michel Seman, Suzanne Bernard, Rene Milcent, Catherine Paillat
-
Patent number: 5767314Abstract: A process for selectively monoacylating monoalkylhydrazines by reacting such with trichloromethyl aryl ketones.Type: GrantFiled: September 23, 1993Date of Patent: June 16, 1998Assignee: Rohm and Haas CompanyInventors: Martha Jean Kelly, Anne Marie Budenz
-
Patent number: 5753684Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.Type: GrantFiled: June 6, 1995Date of Patent: May 19, 1998Assignee: The Picower Institute for Medical ResearchInventors: Marina Bianchi, Anthony Cerami, Kevin J. Tracey, Peter Ulrich
-
Patent number: 5684197Abstract: A process for producing a hydrazide of the formula: ##STR1## is disclosed. The process comprises reacting a hydrazone of the formula: ##STR2## wherein said hydrazone is in toluene, with a mixture of Grignard reagents, wherein said Grignard reagents are in a suitable organic solvent; wherein: (A) Z is a suitable carbonyl protecting group; (B) R is a suitable --OH protecting group; (C) R.sup.1 is selected from: H, a non-enolizable alkyl, a non-enolizable substituted alkyl, aryl, substituted aryl, --S-aryl, --S-(substituted aryl), --S-alkyl, --S-(substituted alkyl), alkoxy, substituted alkoxy, aryloxy, or substituted aryloxy; (D) said mixture of Grignard reagents comprises R.sup.2 MgX in admixture with R.sup.3 MgX; (E) R.sup.2 is a suitable alkyl, substituted alkyl, alkenyl, alkynyl, aryl, substituted aryl, or aralkyl group capable of adding to the --C.dbd.N group of the hydrazone to produce the hydrazide; (F) R.sup.Type: GrantFiled: December 12, 1996Date of Patent: November 4, 1997Assignee: Schering CorporationInventors: William Leong, Lyman Smith
-
Patent number: 5675037Abstract: This application relates to a process for selectively monoacylating hydrazines by reacting unsubstituted or monoalkylhydrazines with trichloromethyl aryl ketones.Type: GrantFiled: December 17, 1990Date of Patent: October 7, 1997Assignee: Rohm and Haas CompanyInventor: Martha J. Kelly
-
Patent number: 5672723Abstract: The present invention can provide a process for the preparation of an 1-acyl-2-substituted hydrazine compound from a mixture containing the 1-acyl-2-substituted hydrazine and an 1-acyl-1-substituted hydrazine by selective hydrolysis or alcoholysis of the 1-acyl-yl-1-substituted hydrazine in the presence of an acid catalyst, and by separation of the resulting carboxylic acid and derivative thereof.The 1-acyl-2-alkyl hydrazine obtained has a high purity.Type: GrantFiled: February 21, 1996Date of Patent: September 30, 1997Assignees: Nippon Kayaku Kabushiki Kaisha, Sankyo Company, LimitedInventors: Hiroki Hotta, Hiroyasu Sugizaki, Tetsuya Toya, Mikio Yanagi
-
Patent number: 5599984Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.Type: GrantFiled: September 29, 1994Date of Patent: February 4, 1997Assignee: The Picower Institute For Medical ResearchInventors: Marina Bianchi, Anthony Cerami, Kevin J. Tracey, Peter Ulrich
-
Patent number: 5567723Abstract: Compounds having the structural formula ##STR1## wherein R is C.sub.1 -C.sub.6 alkoxy or C.sub.1 -C.sub.6 alkyl; R.sup.1 is fluorenyl, thienyl, pyridyl or thiazolyl, unsubstituted or substituted by one or more substituents selected from C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkylthio, halogen, C.sub.1 -C.sub.4 haloalkyl and nitro; and R.sup.2 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.6 haloalkyl, C.sub.2 -C.sub.6 alkenyl, or C.sub.2 -C.sub.6 alkoxyalkyl. The compounds of this invention are effective for controlling mites and nematodes.Type: GrantFiled: July 5, 1995Date of Patent: October 22, 1996Assignees: Uniroyal Chemical Company, Inc., Uniroyal Chemical Ltd./LteeInventors: Mark A. Dekeyser, Derek J. McPhee, Paul T. McDonald
-
Patent number: 5543571Abstract: A process for the asymmetric hydrogenation of N-acylhydrazones to optically active N-acylhydrazines in the presence of a chiral phospholane catalyst complex, a process for the reductive N--N bond cleavage of N-acylhydrazine to amines with samarium diiodide, and a multistep process for converting keto group-bearing compounds to the corresponding optically active amino group-bearing compounds are disclosed.Type: GrantFiled: March 7, 1995Date of Patent: August 6, 1996Assignee: E. I. Du Pont de Nemours and CompanyInventor: Mark J. Burk
-
Patent number: 5426223Abstract: A process for the asymmetric hydrogenation of N-acylhydrazones to optically active N-acylhydrazines in the presence of a chiral phospholane catalyst complex, a process for the reductive N--N bond cleavage of N-acylhydrazine to amines with samarium diiodide, and a multistep process for converting keto group-bearing compounds to the corresponding optically active amino group-bearing compounds are disclosed.Type: GrantFiled: July 30, 1993Date of Patent: June 20, 1995Assignee: E. I. Du Pont de Nemours and CompanyInventor: Mark J. Burk
-
Patent number: 5399589Abstract: Oxalyl hydrazide-hydroxamic acid derivatives of the formula I ##STR1## where the substituents have the following meanings: R, R.sup.1, R.sup.2 and R.sup.3 independently of one another arehydrogen, substituted or unsubstituted alkyl, alkenyl or alkynyl orsubstituted or unsubstituted cycloalkyl or cycloalkylmethyl,substituted or unsubstituted cycloalkenyl or cycloalkenylmethyl,substituted or unsubstituted phenyl, phenylalkyl, phenylalkenyl, hetaryl- or hetarylalkyl radicals, where R.sup.2 and R.sup.3 may also. together with the nitrogen atom whose substituents they are, form a 5- or 6-membered ring, orR.sup.2 together with R.sup.3 is the group ##STR2## where R.sup.4 and R.sup.5 are one of the radicals R, R.sup.1, R.sup.2 or R.sup.3, or R.sup.4 together with R.sup.5 and the carbon atom whose substituents they are, are monocyclic or polycyclic cycloalkyl, orR.sup.4 together with R.sup.5 and the carbon atom whose substituents they are, form a 5- or 6-membered, saturated heterocycle containing O, S or --N(R.sup.Type: GrantFiled: November 29, 1993Date of Patent: March 21, 1995Assignee: BASF AktiengesellschaftInventors: Costin Rentzea, Albrecht Harreus, Eberhard Ammermann, Gisela Lorenz
-
Patent number: 5399758Abstract: Disclosed are a novel azide compound represented, for example, by the formula, ##STR1## wherein R.sub.f represents a fluoroalkyl or fluoroalkylpolyether group, ##STR2## wherein R represents a divalent organic group having an ester bond, and R.sub.f ' represents a fluoroalkylpolyether group, and a novel diacylhydrazine compound having a fluoroalkylpolyether group in the side chain and lubricants containing them. When this lubricant is coated onto the carbonaceous protective film of magnetic recording media and reacted by the action of light or heat, it strongly bonds or adheres to the protective film. Thus, the durability of the lubricant improves, as a result of which a high-density magnetic recording medium having a high reliability and long life can be obtained.Type: GrantFiled: November 20, 1992Date of Patent: March 21, 1995Assignee: Hitachi, Ltd.,Inventors: Toshimasa Miura, Ryoichi Sudo, Saori Matsuda, Fumio Kataoka
-
Patent number: 5378729Abstract: The present invention relates to compounds exhibiting central nervous system (CNS) activity which are useful in the treatment of epilepsy and other CNS disorders. The compounds of this invention have the following general formula: ##STR1## and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 4, 1991Date of Patent: January 3, 1995Assignee: Research Corporation Technologies, Inc.Inventors: Harold L. Kohn, Darrell Watson
-
Patent number: 5367093Abstract: Compounds having the structural formula ##STR1## where X, Y, R and Z are defined in the specification are disclosed. The compounds of this invention are effective for controlling mites, nematodes, rice planthopper, tobacco budworm, and southern corn rootworm. Methods for making these compounds are also set forth.Type: GrantFiled: November 20, 1992Date of Patent: November 22, 1994Assignees: Uniroyal Chemical Company, Inc., Uniroyal Chemical LTD/LTEEInventors: Mark A. Dekeyser, Paul T. McDonald
-
Patent number: 5276140Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--XwhereinL is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from: ##STR1## wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue briding the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected from--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --a)wherein each n2 is independently 2-4 and ##STR2## wherein n3 is 2-6. Also claimed are hydrazides, semicarbazides, and thiosemicarbazides of .omega.-mercaptocarboxylic acids which lack SPACER diamine.Type: GrantFiled: January 9, 1991Date of Patent: January 4, 1994Assignee: Cetus Oncology CorporationInventors: Danute E. Nitecki, Margaret Moreland